About the Event
Kineta is developing the next generation immunotherapies for cancer patients.
- Initiating Phase 1 study in Q4 2022
- Partnerships in place with Genentech, Merck, and Fair Therapeutics
- They will become a NASDAQ listed company in late 2022
Their first drug targets non-small cell lung cancer, ovarian cancer, and colorectal cancer with a combined market opportunity of $48B.
Join our webinar to hear how Kineta’s platform will transform Immunotherapy for generations to come.